GLP-1
Retaglutide(Retatrutide)
Retatrutide
Own facility · GLP-1 Peptides
Investigational. This is an investigational compound and is not approved for marketing. Material and development services are offered only to qualified entities for research and pharmaceutical development, subject to applicable law.
Retatrutide is an investigational triple GIP / GLP-1 / glucagon receptor agonist in clinical development for obesity and metabolic disease. BOOKPHARM supports retatrutide through CDMO development and active-ingredient supply.
Supply offerings
| Business line | Business model | Regulatory status |
|---|---|---|
| FDFGLP-1 | API + FDF CMO/Supply | CDMO |
| APIGLP-1 | API supply | NDC+US DMF |
Supplied for pharmaceutical manufacturing and R&D by licensed and qualified entities. Not for human use as supplied. Availability is subject to regulatory approval in the buyer's jurisdiction.